Myogenic Underactive Bladder and Heart Failure Resemblance: A Novel Role for SGLT2 Inhibition?

Autores da FMUP

• Gabriel Faria Da Costa

  Autor

• Ana Cristina Estrela De Oliveira Charrua Cordeiro

  Autor

• Carlos Manuel Pires Martins Da Silva

  Autor

• Joaquim Adelino Correia Ferreira Leite Moreira

  Autor

• Tiago Vieira Da Conceicao Antunes Lopes

  Autor

Unidades de investigação

• Biomedicina

• Cirurgia e Fisiologia

• Laboratório Associado RISE- Rede de Investigação em Saúde

  

  Investigador

  Fernando Carlos De Landér Schmitt

• RISE-Health

  

  Investigador

  Fernando Carlos De Landér Schmitt

Abstract

The heart and bladder share physiological biomechanical determinants of contraction. Heart failure (HF) and myogenic underactive bladder (mUAB) also share similarities in their pathophysiology. In both cases there is muscle injury that is directly linked to disease stage. In the final stage, both myocardium and detrusor show marked fibrosis and lower contractility. While HF has an established pharmacological treatment, there are still no effective drugs for mUAB. This mini-review explores the similarities between HF and mUAB and suggests that, as in HF, SGLT2 inhibitors may also have a beneficial role in mUAB. Patient summary: To date, there is no treatment for underactive bladder caused by problems with the bladder muscle (mUAB). We review similarities between this condition and heart failure and hypothesize that a recent drug class with striking results in heart failure might also have a beneficial role in mUAB. (C) 2022 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Copyright © 2022 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Keywords

• Underactive bladder; Heart failure; Diabetic cystopathy; Bladder remodeling; SGLT2; Inhibitor